Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Find out how a groundbreaking energy control map of the brain could revolutionise obesity treatment Learn about the complex ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

The stock market in 2025 resembles a chessboard of extremes. While volatility is shaking up markets, extraordinary ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...